ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Biodesix Inc

Biodesix Inc (BDSX)

1.71
0.10
(6.21%)
Closed June 21 4:00PM
1.71
0.00
( 0.00% )
Pre Market: 7:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.71
Bid
1.70
Ask
1.71
Volume
100
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.71
Open
-
Last Trade
50
@
1.71
Last Trade Time
07:00:06
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
114,685,783
Dividend Yield
-
PE Ratio
-3.76
Earnings Per Share (EPS)
-0.45
Revenue
49.09M
Net Profit
-52.15M

About Biodesix Inc

Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic researc... Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Wilmington, Delaware, USA
Founded
1970
Biodesix Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker BDSX. The last closing price for Biodesix was $1.71. Over the last year, Biodesix shares have traded in a share price range of $ 0.00 to $ 0.00.

Biodesix currently has 114,685,783 shares outstanding. The market capitalization of Biodesix is $196.11 million. Biodesix has a price to earnings ratio (PE ratio) of -3.76.

BDSX Latest News

Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”

Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list. The...

Biodesix to Participate in Two Investor Conferences in June

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AGFYAgrify Corporation
$ 0.4698
(86.43%)
21.45M
ALIMAlimera Sciences Inc
$ 5.57
(76.83%)
468.44k
ALNYAlnylam Pharmaceuticals Inc
$ 225.00
(35.79%)
238.36k
EPOWSunrise New Energy Company Ltd
$ 0.805
(34.32%)
4.13M
RGLSRegulus Therapeutics Inc
$ 3.17
(26.29%)
2.18M
EFTReFFECTOR Therapeutics Inc
$ 0.3922
(-66.48%)
165.24k
GTHXG1 Therapeutics Inc
$ 1.13
(-54.44%)
216.38k
DMTKDermTech Inc
$ 0.0871
(-23.73%)
2.38M
FUFUBitFuFu Inc
$ 4.83
(-22.10%)
99.11k
LPTXLeap Therapeutics Inc
$ 1.53
(-20.31%)
50
AGFYAgrify Corporation
$ 0.474
(88.10%)
21.47M
WBUYWeBuy Global Ltd
$ 0.1904
(6.55%)
8.07M
CRKNCrown Electrokinetics Corporation
$ 0.0352
(-14.36%)
7.42M
NVDANVIDIA Corporation
$ 123.88
(-2.13%)
6.6M
SOBRSOBR Safe Inc
$ 0.218
(23.44%)
5.29M

BDSX Discussion

View Posts
AJ Freely AJ Freely 11 months ago
$BDSX - Up 12%/ Current Price $1.34.
Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
👍️0
1hot toddy 1hot toddy 2 years ago
WOOOOOOW 130K SHARES BUY NOW 2.6 MIL SHARE BUY $

3 MILLION $ BUY $$$$$$$$$$$$$$$$$$$$$$
👍️0
Leg58 Leg58 2 years ago
Lots if potential but will public offering dilute price?
👍️0
Leg58 Leg58 2 years ago
Lots if potential but will public offering dilute price?
👍️0
subslover subslover 2 years ago
Earnings look good.
👍️0
subslover subslover 2 years ago
Earnings look good.
👍️0
MiamiGent MiamiGent 2 years ago
BDSX Has news this morning!

The contract covers the company’s entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS™ testing.

https://investors.biodesix.com/news-releases/news-release-details/biodesix-awarded-us-federal-supply-schedule-contract-its

https://stockcharts.com/h-sc/ui?s=BDSX
👍️0
carusso carusso 2 years ago
Not so much...
👍️0
crudeoil24 crudeoil24 2 years ago
LET'S GO BDSX !!!!!
👍️0
crudeoil24 crudeoil24 2 years ago
Biodesix to Participate in Two Upcoming Investor Conferences in September
6:00 am ET September 6, 2022 (BusinessWire) Print
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.

H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings Location: Lotte New York Palace Hotel, New York, NY
👍️0
crudeoil24 crudeoil24 2 years ago
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
👍️0
Leg58 Leg58 2 years ago
US based company is quietly trending up. IMHO.
GLTA
👍️0

Your Recent History

Delayed Upgrade Clock